Alvotech (ALVO) Net Margin (2022 - 2026)
Alvotech's (ALVO) quarterly Net Margin came in at 121.81% in Q2 2026, down 10766.0% on a YoY basis from N/an in Q2 2025, and down 6718.19% quarter-over-quarter from 1.84% in Q1 2026.
Powered by 
Analysis
Alvotech (ALVO) Net Margin (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Net Margin for 5 consecutive years, with 121.81% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 10766.0% year-over-year to 121.81%; the trailing twelve-month figure through Jun 2026 stood at 81.18% (down 2780.0% YoY), and the FY2025 full-year result was 88.6%, up 16293.0% from the prior year.
- Net Margin retreated to 121.81% in Q2 2026 per ALVO's latest filing, from 1.84% in the prior quarter.
- Across five years, Net Margin topped out at 2165.79% in Q2 2023 and bottomed at 14463.89% in Q4 2022.
- Historically, Net Margin has averaged 1504.58% across 5 years, with a median of 91.58% in 2026.
- The sharpest annual moves came in 2023 and 2024: Net Margin surged 1084840 bps in 2023, then sank 200056 bps in 2024.
- Over 5 years, Net Margin stood at 14463.89% in 2022, then soared by 75 bps to 3615.49% in 2023, then jumped by 91 bps to 308.38% in 2024, then jumped by 110 bps to 31.14% in 2025, then slumped by 491 bps to 121.81% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 121.81%, 1.84%, and 31.14% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.95 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.89 Bn | 9.71 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.33 Bn | 490.75 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 994.86 Mn | 704.74 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 400.03 Mn | 358.78 Mn | 17.15 Mn | 11.04% |
| 10 | RedHill Biopharma | 179.86 Mn | 179.86 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -121.81% |
| Mar 31, 2026 | 1.84% |
| Dec 31, 2025 | 31.14% |
| Sep 30, 2025 | -847.46% |
| Jun 30, 2025 | -14.15% |
| Mar 31, 2025 | 70.21% |
| Dec 31, 2024 | -308.38% |
| Sep 30, 2024 | -61.36% |
| Jun 30, 2024 | 165.22% |
| Mar 31, 2024 | -1,863.27% |
| Dec 31, 2023 | -3,615.49% |
| Aug 31, 2023 | -821.32% |
| Jun 30, 2023 | 2,165.79% |
| Dec 31, 2022 | -14,463.89% |
| Aug 31, 2022 | -5,559.94% |
| Jun 30, 2022 | 1,169.60% |